



Epichem Export Business Receives Important WA State Awards

4th October 2019 – Perth, Australia: PharmAust Ltd (ASX:PAA), a clinical-stage oncology company, is pleased to announce that its Perth-based synthetic and medicinal chemistry subsidiary Epichem Pty Ltd is a winner in this year's prestigious Western Australian Industry and Export Awards.

Epichem has been successfully exporting specialised contract research services and products to clients worldwide for over 15 years. The WA Industry and Export Awards acknowledges forward thinking companies in the State and their contributions to economic diversity. Managed by the Export Council of Australia, the awards recognise and honour the "Best of the Best" in Western Australian business.

Last week Epichem was delighted to be presented with the WA Industry Export Award 2019 for International Health. Epichem makes significant contributions to the global health and biotechnology sector by providing end-to-end support in drug discovery.

Epichem's CEO Dr Martine Keenan said "We often work behind the scenes on drug discovery projects and with drug manufacturers, so it's wonderful to receive recognition for the high-quality contributions by the Epichem team. Congratulations to all the Epichem team. The Company cannot achieve accolades like this without talented and dedicated people to drive the science forward and deliver the high level of customer service."

Epichem CEO Dr Martine Keenan was also presented with the Women in International Business Award. "It's been wonderful to help Epichem grow and mature in the 11 years that I've been here," Martine said. "Whilst I picked up the award, it is certainly not something I have achieved alone. Epichem staff past and present have all made major contributions to the Company's success, which is why we are still going strong with a bright and exciting future."

"Epichem's highly awarded export business continues to drive significant revenue growth," commented PharmAust Chairman Dr Roger Aston. "Congratulations to Martine and her team. We wish Epichem all the best in Canberra for the National Awards night later this year."

Enquiries:

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

Dr Martine Keenan
Epichem CEO
Tel: 0424 253 011
martine.keenan@epichem.com.au



About PharmAust (PAA):

PAA is a clinical-stage company developing targeted cancer therapeutics for humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. PAA's subsidiary, Epichem, is a successful contract medicinal chemistry company that is forecasting \$4.2m revenues in FY2019/20.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs; was well tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug in Phase 2 clinical trials.

About Epichem:

Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited. Located in Technology Park, Western Australia, Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in over 40 countries worldwide for over 15 years. Epichem has newly constructed state-of-the-art laboratories and has world class equipment and expertise in synthetic and medicinal chemistry to support drug discovery projects, and for the cost-effective synthesis of drug analogue libraries and intermediates. It also has a rapidly growing catalogue of pharmaceutical reference standards. Epichem has forecast \$4.2m in revenues in the 2020 FY. Please find more information at www.epichem.com.au